1 / 15

E. Martínez , M. Larrousse, I. Pérez, M. Loncá,

No Evidence for Recent Abacavir/Lamivudine Use in Promoting Inflammation, Endothelial Dysfunction, Hypercoagulability, or Insulin Resistance in Virologically Suppressed HIV-infected patients: A Sub-study of the BICOMBO Randomized Clinical Trial. E. Martínez , M. Larrousse, I. Pérez, M. Loncá,

devon
Download Presentation

E. Martínez , M. Larrousse, I. Pérez, M. Loncá,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. No Evidence forRecent Abacavir/Lamivudine Use in Promoting Inflammation, Endothelial Dysfunction, Hypercoagulability, or Insulin Resistance in Virologically Suppressed HIV-infected patients:A Sub-study of theBICOMBO Randomized Clinical Trial E. Martínez, M. Larrousse, I. Pérez, M. Loncá, D. Podzamczer, F. Gutiérrez, R. Deulofeu, R. Casamitjana, J.C. Reverter, J. Mallolas, J. Pich, J.M. Gatell, for the BICOMBO Study Group SPAIN

  2. ABACAVIR AND CV DISEASE • Abacavir use identified as a marker of cardiovascular disease in several cohort studies (1-3), although it is currently unclear whether its role is causative or not. • Potential pathogenetic mechanisms are also unclear. Abacavir has not been asociated with insulin resistance (4) or lipoatrophy (4, 5) and its lipid impact is lower than that of stavudine (5) or protease inhibitors (6), although higher than that of tenofovir (7). • Several potential mechanisms affecting biological mechanisms associated with cardiovascular dysfunction have been suggested (6-8) but studies to date may have been subjected to bias. 1. D:A:D Study Group. Lancet 2008; 371: 1417-1426 2. The SMART/INSIGHT and the D:A:D Study Groups. AIDS 2008; 22: F17-F24 3. Obel N, et al. HIV Medicine 2009 (Epub ahead of print) 4. Shlay JC, et al. JAIDS 2005; 38: 147-155 5. Podzamczer D, et al. J Acquir Immune Defic Syndr. 2007; 44: 139-147 6. Martinez E, et al. N Engl J Med 2003; 349: 1036-1046 7. Smith KY, et al. AIDS 2009; 23: 1547-1556 6. Hsue PY, et al. AIDS. 2009; 23: 2021-2027 7. Satchell C, et al. 16th CROI, 2009. Montreal, Canada. Abstract 151LB 8. Kristoffersen US, et al. HIV Medicine 2009 (Epub ahead of print)

  3. D:A:D STUDY: ABC, TDF, and MYOCARDIAL INFARCTION Cumm. use 1.9 Recent use 1.5 1.5 RRyes/no 95%CI 1.2 RR per year 95%CI 1.2 ** 1 1 0.8 0.8 0.6 0.6 J Lundgren & DAD Study Group et al CROI 2009 LB abstr 44

  4. MECHANISMS FOR MYOCARDIAL INFARCTION 3 TDF Complication Initiation Progression Inflammation Hypercoagulability Endothelial dysfunction Insulin resistance 1-3 ABC 1. D:A:D Study Group. Lancet 2008. 2. The SMART/INSIGHT and the D:A:D Study Groups. AIDS 2008. 3. D:A:D Study Group. CROI 2009.

  5. POTENTIAL SOURCES OF CONFOUNDING AND BIAS • Drug prescription not random • Pre-existing CV disease or DM • Uncontrolled HIV infection or AIDS

  6. BICOMBO STUDY DESIGN Patients randomized (n=335) PI=34 NNRTI=301 • Stable 3TC-based ART for > 6 months • HIV-RNA < 200c/mL • No HLA screening TDF/FTC (n=168) ABC/3TC (n=167) Excluded (n=0) Excluded (n=2) ABC/3TC (n=167) TDF/FTC (n=166) Primary Analysis, Week 48 Discontinue TDF/FTC (n=22, 13%) Discontinue ABC/3TC (n=30, 18%) Continue on ABC/3TC (n=137, 82%) * Continue on TDF/FTC (n=144, 87%) * 1 patient with virological failure and 1 with a new AIDS event Martinez E et al. J Acquir Immune Defic Syndr 2009.

  7. METHODS • Patients • Baseline and 48w serum samples available • No history of symptomatic CV disease or DM • No virological failure or AIDS events during follow-up • Laboratory markers • Statistical analyses • Wilcoxon rank Sum test for comparisons • Punctual estimation and 95% confidence interval of difference in medians (methodology of Hodges-Lehman, using the distribution-free of Moses). • Spearman test for correlations Complication Initiation Progression Inflammation Hypercoagulability Endothelial dysfunction Insulin resistance D-dimer hsCRP, MCP-1 OPG, IL-6 TNF-alpha IL-10 ICAM-1, VCAM-1 Selectin E, Selectin P Adiponectin, Insulin

  8. POPULATION CHARACTERISTICS P>0.05 for all comparisons between groups (ABC/3TC vs TDF/FTC) in the Sub-study. P>0.05 for all comparisons between patients in the Sub-study vs patients from the BICOMBO study not in the Sub-study.

  9. BIOMARKERS AT BASELINE and 48 WEEKS

  10. CORRELATIONS BETWEEN BASELINE PARAMETERS

  11. CHANGE IN BIOMARKERS FROM BASELINE TO 48 WEEKS

  12. CHANGE IN HIGH-SENSITIVITY CRP Because hsCRP is the marker with more widespread clinical use, we performed additional analyses. Absolute hsCRP increase at 48 weeks: 18(39%) and 11 (32%) patients in the ABC/3TC and TDF/FTC groups respectively (P=0.62). hsCRP higher than 0.5 mg/dL at 48 weeks: 4(9%) and 1 (3%) patients in the ABC/3TC and TDF/FTC groups respectively (P=0.39). hsCRP increase at 48 weeks 25% higher than that at the baseline: 16(35%) and 9 (26%) patients in the ABC/3TC and TDF/FTC groups respectively (P=0.61).

  13. CONCLUSIONS In otherwise healthy, virologically suppressed HIV-infected patients from the BICOMBO study, the initiation of ABC/3TC did not lead to significant changes after 48 weeks in markers of inflammation, endothelial dysfuntion, insulin resistance, or hypercoagulability as compared with the initiation of TDF/FTC. These results argue against any of these mechanisms as involved in the higher risk of MI associated with recent ABC use in some cohort studies.

  14. ACKNOWLEDGEMENTS Supported in part by research grants from Gilead Sciences and GlaxoSmithKline Participating centers and investigators (in alphabetical order): Hospital de Bellvitge, L’Hospitalet (Patricia Barragán, Elena Ferrer, Daniel Iñiguez, Gabriela Leibenger, Daniel Podzamczer) Hospital Clínic, Barcelona (Mireia Arnedo, José L Blanco, Marta Calvo, José M Gatell, Montserrat Laguno, María Larrouse, Agathe León, Montserrat Loncá, Josep Mallolas, Esteban Martínez, María Martínez, Ana Milinkovic, José M. Miró, Tomás Pumarola) Hospital Clínico de San Carlos, Madrid (Mónica Fuster, Victor Roca†) Hospital General Universitario de Elche, Elche (Enrique Bernal, Félix Gutiérrez, Mar Masiá, Sergio Padilla). Hospital Germans Trías i Pujol, IrsiCaixa Foundation, Badalona (Isabel Bravo, Bonaventura Clotet, Patricia Echeverría). Hospital Gregorio Marañón, Madrid (Juan Berenguer, Jaime Cosín, Isabel Gutiérrez, Margarita Ramírez, Matilde Sánchez) Hospital Universitari de Tarragona Joan XXIII, Universitat Rovira i Virgili, Tarragona (Joaquim Peraire, Francesc Vidal) Hospital del Mar, Barcelona (Hernando Knobel, Alicia González) Hospital de Mataró, Mataró (Luis Force, Pilar Barrufet) Hospital de Mútua de Terrassa, Terrassa (Mireia Cairó, David Dalmau, Carol García) Hospital Parc Taulí, Sabadell (Esperanza Antón, Eva Penelo, Ferran Segura) Hospital Universitario La Paz, Madrid (José R Arribas, Juan Miguel Castro, María Montes) Hospital Universitario de La Princesa, Madrid (Raquel Carrillo, Ignacio de los Santos) Hospital Príncipe de Asturias, Alcalá de Henares (Jose A Arranz, Esperanza Casas, Julio de Miguel, José Sanz) Hospital Sant Jaume, Calella (Josep M Llibre, Silvia Valero) Hospital Son Llàtzer, Palma de Mallorca (Antoni Payeras) Hospital de Sierrallana, Torrelavega (Francisco Galo) Hospital Vall d’Hebron, Barcelona (Esteban Ribera, Adrià Curran) Special thanks to study patients

More Related